Advanced Tumors
21
6
6
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
3 terminated out of 21 trials
70.0%
-16.5% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (21)
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
A Study of AL58805 in Patients With Advanced Tumors
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)
A SHR-1210 BE Study on Healthy Subjects
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
A Study of HRS2543 in Patients With Advanced Tumors
A Study of CS23546 in Subjects With Advanced Tumors
Phase I Study of CPI-300 in Patients With Advanced Tumors
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
A Study of PM1022 in Patients With Advanced Tumors
Study of CPI-100 in Patients With Advanced Tumors
Study of BMS-986158 in Subjects With Select Advanced Cancers
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor